Merck: launch of a phase 3 study in lymphoma

(CercleFinance.com) - Merck announced on Thursday the start of a Phase 3 clinical trial to assess the efficacy of its antibody-drug conjugate zilovertamab vedotin in the treatment of diffuse large B-cell lymphoma.


The aim of the trial is to compare the efficacy of the product in combination with the so-called "R-CHP" protocol, which combines rituximab, cyclophosphamide, doxorubicin and prednisone, with that of the R-CHP protocol alone.

The trial, which is currently recruiting its first patients, aims to enroll a total of 1,046 participants.

In a press release, Merck recalls that zilovertamab vedotin, which has not yet been granted any marketing authorization, had obtained 'encouraging' results in phase 2.

Copyright (c) 2025 CercleFinance.com. All rights reserved.